Navigation Links
GranuFlo Lawsuit News: Bernstein Liebhard LLP Comments on Fresenius FDA Warning Letter, as GranuFlo Recall Claims Mount
Date:8/31/2013

New York, New York (PRWEB) August 31, 2013

As GranuFlo lawsuits (http://www.granuflodialysislawsuits.com/) filed in the aftermath of Fresenius Medical Care’s recall of GranuFlo and NaturaLyte dialysis concentrates continue to mount, Bernstein Liebhard LLP notes that another Fresenius entity recently received a Warning Letter from the U.S. Food & Drug Administration (FDA) for problems at a manufacturing plant in Puerto Rico. According to a report from Reuters, the letter cited issues with complaint-handling procedures and labeling at a Fresenius Kabi facility that manufactures blood bags.*

“The FDA was already investigating Fresenius for its handling of the GranuFlo recall. Taken as a whole, these issues are certainly concerning,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis treatments.

GranuFlo Recall

This marks the second FDA Warning Letter received by a Fresenius entity since March 2013. That month, Fresenius Medical Care North America was cited by the agency for issues at a plant in Ogden, Utah. That same entity was also behind the GranuFlo recall, which was issued in March 2013 after GranuFlo and NaturaLyte were linked to a rapid and unsafe elevation of bicarbonate, which creates a substantially increased risk of cardiopulmonary arrest and death. The GranuFlo recall was eventually given the FDA’s most serious recall designation, Class I.**

The New York Times reported last summer that the FDA had launched an investigation of Fresenius Medical Care’s handling of the GranuFlo recall, after learning that the company had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. However, nothing was done at that time to notify thousands of dialysis centers outside the Fresenius network about the potential dangers associated with the products.***

According to court records, more than 300 GranuFlo lawsuits alleging personal injury and death due to the use of GranuFlo and NaturaLyte have been filed in a federal multidistrict underway in U.S. District Court, District of Massachusetts. All of the pending claims allege that Fresenius Medical Care failed to provide adequate warnings regarding the use of the products, and assert that the company continued to aggressively market the drugs even after the company became aware of their dangers. The Court is scheduled to hold a conference in the proceeding on September 27, 2013. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

Dialysis patients who suffered serious heart problems, including cardiac arrest, heart attacks, stroke, and sudden cardiac death, within 48 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to compensation for their injury-related damages. Learn More about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092.

*reuters.com/article/2013/08/23/fresenius-fda-idUSWEB00AFY20130823, Reuters, August 23, 2013
**fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm, FDA March 29, 2012
***nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.granuflodialysislawsuits.com/

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11079971.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuits News: Calif. Lawsuit Alleges Drug Maker Hid Serious Health Risks, Rottenstein Law Group LLP Reports
2. 201 Actions Pending in the Granuflo Multidistrict Litigation: Now, AttorneyOne Can Provide Advice
3. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal GranuFlo Recall Litigation
4. NaturaLyte and GranuFlo Lawsuits Are Heating Up
5. New Fresenius NaturaLyte, GranuFlo Dialysis Heart Attack Lawsuit Allegations Update: Resource4thePeople Reports Important Hearing Is Scheduled in Fresenius Multidistrict Litigation
6. Rottenstein Law Group LLP Announces Launch of GranuFlo Lawsuit Center
7. GranuFlo Recall Lawyers at Wright & Schulte LLC Investigating GranuFlo Lawsuits on Behalf of Dialysis Patients Allegedly Injured by GanuFlo or NaturaLyte
8. Granuflo Multidistrict Litigation Moves Forward: Now, AttorneyOne Can Provide Advice
9. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
10. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
11. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... is proud to announce a new informational post on robotic hair transplantation. San ... Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five states ... And the need for advanced services is growing. , Project WE vs C ... in collaboration with their non-profit partners in their fight against cancer and in support ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards & ... International Social Design Awards. , The 7th A' Social Design Award is ... Institutions worldwide with realized projects and conceptual works. , The first phase of ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... PA (PRWEB) , ... February 26, 2017 , ... ... and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. ... Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)... AUSTIN, Texas , Feb. 27, 2017  International Biophysics ... Austin, Texas , today announced a 34% revenue growth ... a 53% increase in unit sales.  This growth was fueled ... in addition to the expansion of its global ... Shockley, Jr., International Biophysics, CEO, "As we enter our 25 ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology: